Merrithew & Thorsten Inc’s Biogen BIIB Stock Holding History

Merrithew & Thorsten Inc’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22K	Hold	106	–	–	0.02%	62
2026 Q1	$19K	Hold	106	–	–	0.02%	63
2025 Q4	$18K	Buy	+106	New	+$17.3K	0.02%	64

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Merrithew & Thorsten Inc's BIIB Position: Q2 2026 in Review

Merrithew & Thorsten Inc held its Biogen (BIIB) position steady in Q2 2026 at 106 shares worth $22K. The position accounts for 0.02% of the portfolio, ranked #62.

Merrithew & Thorsten Inc first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Merrithew & Thorsten Inc held 106 shares of Biogen worth $22K as of Q2 2026.
Merrithew & Thorsten Inc left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.02% of Merrithew & Thorsten Inc's portfolio in Q2 2026, its #62 holding.
Merrithew & Thorsten Inc first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Merrithew & Thorsten Inc's 13F filing for Q2 2026, filed 31 Jul 2026.